Stephen Furlong Sells 14,836 Shares of Neuronetics, Inc. (NASDAQ:STIM) Stock

Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong sold 14,836 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $3.28, for a total transaction of $48,662.08. Following the sale, the chief financial officer now directly owns 482,572 shares in the company, valued at $1,582,836.16. This trade represents a 2.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Neuronetics Stock Performance

Shares of STIM stock opened at $3.90 on Friday. Neuronetics, Inc. has a one year low of $0.52 and a one year high of $5.07. The company’s 50-day moving average is $2.14 and its 200 day moving average is $1.40. The company has a market capitalization of $118.37 million, a price-to-earnings ratio of -3.17 and a beta of 2.17. The company has a debt-to-equity ratio of 4.90, a quick ratio of 2.87 and a current ratio of 3.16.

Institutional Trading of Neuronetics

A number of institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd purchased a new stake in shares of Neuronetics during the 4th quarter valued at about $49,000. Geode Capital Management LLC boosted its holdings in shares of Neuronetics by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 314,076 shares of the company’s stock valued at $506,000 after acquiring an additional 8,466 shares during the last quarter. Tradewinds LLC. purchased a new stake in shares of Neuronetics during the 4th quarter valued at about $32,000. JPMorgan Chase & Co. boosted its holdings in shares of Neuronetics by 10,954.1% during the 4th quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company’s stock valued at $88,000 after acquiring an additional 54,442 shares during the last quarter. Finally, David J Yvars Group boosted its holdings in shares of Neuronetics by 47.1% during the 4th quarter. David J Yvars Group now owns 46,325 shares of the company’s stock valued at $75,000 after acquiring an additional 14,825 shares during the last quarter. Hedge funds and other institutional investors own 53.59% of the company’s stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.